Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.
Torres
Harrys A
HA
Bull
Lara
L
Arduino
Roberto C
RC
Barnett
Ben J
BJ
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D014060:Tongue Diseases / Q000139:chemically induced*; D044465:White People
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b